Dimension Biotechnologies

Based in the UK, Dimension Biotechnologies, operates as a blood-based microvascular health testing and biomarker analysis service provider. Based in the UK and founded in 2025, Dimension Biotechnologies offers innovative diagnostics for microvascular health. In September 2026, the company raised GBP 490,000 in pre-seed funding from investors including Kidney Research UK and the University of Bristol. This funding was part of a larger GBP 705,000 pre-seed and grant round, aimed at scaling operations and advancing technology for early disease detection.

Dimension Biotechnologies focuses on microvascular diagnostics through a novel liquid biopsy method that assesses the health of the endothelial glycocalyx. This technology enables non-invasive analysis, addressing challenges in monitoring microvascular health for diseases such as cardiovascular issues and kidney disease. Their primary customers include healthcare providers and research institutions globally. Dimension Biotechnologies generates revenue through partnerships and direct transactions with hospitals, clinical laboratories, and pharmaceutical firms.

Their business model includes subscriptions or service agreements for ongoing access to diagnostic technology, alongside one-time fees for blood sample analyses, reinforcing their role in clinical decision-making. The company plans to scale up operations and advance its technology for measuring microvascular health through routine blood tests, supporting earlier detection of diseases such as kidney disease, cardiovascular disease, and dementia.